ModernMedicine Resource Center More Topics

Hepatology Resource Center

Some HCV patients still difficult to treatDirect-acting antiviral (DAA) agents appear to have a less robust effect in “difficult-to-treat” patients, according to new research.
Real-world factors aid HCV patient treatment decisionsA new study explores what lifestyle hepatitis C virus (HCV) patients consider when directing their course of treatement.
HCV infection raises risk of developing Parkinson’sA new study indicates that infection with the hepatitis C virus (HCV) significantly increases the risk of developing Parkinson’s Disease.
Antiviral combination eradicates HCV in advanced liver diseaseThe use of sofosbuvir and velpatasvir successfully treated hepatitis C virus infection in 90% of advanced liver disease patients, a new study notes.
Direct-acting antivirals could reduce HCV prevalence by 80%A new study finds that novel direct-acting antiviral therapies might reduce the prevalence of hepatitis C virus and, with enhanced screening and treatment, potentially end infections altogether.
Earlier HCV treatment improves cost effectiveness of care
Earlier HCV treatment improves cost effectiveness of careTreating hepatitis C virus (HCV) infection at early stages of fibrosis improves health outcomes and is cost-effective, a new study finds.
One-step test screens for hepatitis C virus infectionsAn easy, cost-effective, one-step test can allow clinicians to screen, detect, and confirm hepatitis C virus (HCV) infections, according to a new study.
Many hepatitis C patients on Medicaid denied drug coverageNearly half of all Medicaid claims for direct-acting antiviral drugs to treat chronic hepatitis C virus infections have been denied in four states recently because they were not considered “a medical necessity,” according to a new study.
New hep C guidelines endorse direct-acting anti-viral agentsNearly all patients with chronic hepatitis C virus (HCV) infections should receive direct-acting anti-viral agents, according to updated guidelines by the American Association for the Study for Liver Diseases and the Infectious Diseases Society of America.
Liver damage underestimated in hepatitis C patients
Liver damage underestimated in hepatitis C patientsClinical studies that rely on diagnostic codes or biopsies to provide evidence of cirrhosis may be underestimating the extent of the disease among hepatitis C patients, according to a new study.